DamID Profiling of CTCF and TEAD3 Binding within Chromosome 9p21 by Sychla, Adam
1 
 
 
 
DamID Profiling of CTCF and TEAD3 Binding within Chromosome 9p21 
 
Research Thesis 
 
Presented in Partial Fulfillment of the Requirements for Graduation “with Research Distinction in 
Molecular Genetics” in the Undergraduate Colleges of The Ohio State University 
 
By 
Adam Sychla 
 
The Ohio State University 
May 2018 
 
Project Advisor: Dr. Christin Burd 
Department of Molecular Genetics, Department of Cancer Biology and Genetics 
Thesis Committee: Dr. Sharon Amacher, Dr. Christin Burd, Dr. Paul Herman, Dr. F. Kay Huebner 
 
  
2 
 
Abstract 
The progression of benign tumor growth is often restricted by oncogene-induced senescence (OIS), a 
state of irreversible cell cycle arrest that frequently involves upregulation of the p16INK4a tumor 
suppressor. Senescence is ultimately controlled by the accumulation of p16INK4a, but the intermediary 
steps which cause p16INK4a transcriptional upregulation are unknown. Here, I employ the DNA 
adenine methyltransferase identification (DamID) assay to investigate protein binding to DNA 
elements within the INK/ARF locus, which encodes p16INK4a. In DamID, an E. coli Dam methylase is 
fused to DNA-binding factors of interest. Interaction of the Dam-fused DNA binding factor with DNA 
causes local adenosine methylation. Patterns of DNA binding can then be investigated using a 
methylation-sensitive restriction enzyme digest followed by qPCR for the region of interest. I selected 
putative INK/ARF binding proteins and made three fusion constructs: Dam-CTCF, Dam-TEAD3, and 
Dam-SMAD3. I mapped the steady-state binding patterns for each of these fusion proteins across the 
90kb INK/ARF regulatory region. In this way, I quantified the usage of several known binding sites 
and identified novel interactions. With this knowledge, we can now investigate how oncogene 
activation remodels DNA-binding factor interactions to engage, and eventually subvert, the tumor 
suppressive functions of the INK/ARF locus. 
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Introduction 
p15INK4b, p16INK4a and p14ARF are encoded by the INK/ARF locus located on chromosome 9p21.3. 
These proteins play an integral role in tumorsuppression and are functionally inactivated in most 
cancers [1]. The locus is organized into two genes, CDKN2A and CDKN2B. CDKN2A consists of four 
exons and generates two distinct mRNA products from separate promoters, one encoding p16INK4a 
and one encoding p14ARF each with a unique first exon (Figure 1).While the last two exons of 
CDKN2Aare shared by both mRNAs, they are translated in different open reading frames (ORFs). In 
this way,CDKN2A encodes two functionally different tumor suppressors without protein homology. 
Upstream of the p14ARF promoter, lies CDKN2B which contains two exons that are spliced together to 
producethe p15INK4b mRNA (Figure 1). 
Protein products of the INK/ARF locus control the cell cycle through two primary pathways. p14ARF 
stabilizes the activity of p53, a tumor suppressor that controls cell cycle arrest, initiates apoptosis, and 
engages mechanisms involved in DNA damage repair [1, 2]. p14ARF achieves this through inhibition of 
the E3 ubiquitin-protein ligase, MDM2,and this action leads to p53 stabilization (Figure 2A)[3]. 
p15INK4b and p16INK4a are involved in the Retinoblastoma (Rb) tumor suppressor pathway [4]. Active 
E2F transcription factors upregulate a collection of genes involved in the G1- to S-phase cell cycle 
transition. Rb binding inhibits E2F activity, but this interaction is lost when Rb is phosphorylated by 
activated Cyclin Dependent Kinase 4 (CDK4) and/or Cyclin Dependent Kinase 6 (CDK6)(Figure 
2B)[6]. CDK4/6 are activated by binding with Cyclin D [4]. p15INK4b and p16INK4a disrupt the interactions 
between CDK4/6 and Cyclin D thereby preventing RB phosphorylation and subsequent cell cycle 
progression (Figure 2C)[3, 4]. In response to stressors, such as telomere shortening, DNA damage, 
or oncogene activation, p16INK4a is upregulatedand cell cyclearrest ensues [1, 5, 6]. This state is 
normally reversible, but long-term upregulation of these proteins results in cellular senescence, a 
state of permanent cell cycle arrest. This mechanism is initiated in response to oncogene activation 
and thus acts as a check against uninhibited growth, termed oncogene-induced senescence (OIS)[1, 
5]. Functional inactivation of p16INK4a allows cells to bypass OIS and progress to form tumors [1, 5]. 
INK/ARF transcription is controlled by a large regulatory region spanning over 90kb on chromosome 
9p21. Multiple genome wide association studies (GWAS) have linked single nucleotide 
polymorphisms (SNPs) in this region to increased risk of cancer and cardiovascular disease (CAD)[7-
9]. Some of the CAD-associated SNPs occur in a putative enhancer region that we dubbed the 
polymorphic regulatory region (PRR). The PRR is located 70 kb to 100kb upstream from the INK/ARF 
locus and was previously shown to enhance luciferase expression in vitro in a genotype-dependent 
manner [10]. In addition to the PRR, a separate study determined that the INK/ARF regulatory region 
contains nine putative enhancer sites dubbed ECAD1-9. Notably, several CAD-associated SNPs are 
distributed within these enhancer sites [7]. These SNPs could potentially inhibit or enhance binding by 
unknown INK/ARF regulatory factors. The 9p21 interval that spans the INK/ARF locus and PRR also 
contains seven binding sites for CCCTC-Binding Factor (CTCF), a chromatin organizer with insulator 
and chromatin looping activities[11-14]. 
To measure the binding of several proteins throughout the INK/ARF locus, I made use of the DNA 
adenine methyltransferase identification (DamID) system. The Dam enzyme, isolated from E. Coli, 
methylates adenine in the DNA sequence, GATC [15-17]. DNA binding proteins fused to Dam lead to 
preferential methylation near the protein binding location (Figure 3A). Since mammalian cells do not 
perform adenine methylation, we can quantitatively measure methylation added by the Dam enzyme 
to identify DNA binding patterns of the protein of interest. To do this, DNA is extracted from cells 
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expressing the Dam fusion protein and digested with DpnII, a methylation-sensitive restriction 
enzyme that will cut only unmethylated GATC sequences. However, methylated GATC sequences 
will remain intact (Figure 3B)[15, 16]. Primers are selected to produce an amplicon containing at least 
one GATC sequence. qPCR is then used to quantify the amount of uncut, methylated DNA which 
correlates with binding of the fusion protein (Figure 3C). The strong propensity of Dam to methylate 
GATC sequences leads to background methylation, which must be accounted for through the 
simultaneous assessment of negative binding control regions [15, 16]. The DamID system has 
several advantages over the more traditional chromatin immunoprecipitation (ChIP) assays [15]. 
DamID does not require protein-specific antibodies and can detect transient interactions that might be 
lost during immunoprecipitation [15]. Further, because Dam acts to methylate any DNA in its 
proximity, dynamic chromatin loops can also be investigated. Loops will allow for methylation to occur 
even when the transcription factor binds several kilobases away (Figure 4)[18, 19]. In this way, the 
DamID assay investigates the relative three-dimensional positioning of regions of DNA and binding 
proteins. 
My investigation focused on using the DamID assay to determine how several putative INK/ARF 
binding proteins interacted with the locus and the 90kb regulatory region. Future investigations will 
look at changes in 9p21 protein occupancy that may occur during OIS or as a result of 
polymorphisms in the regulatory region. 
Methods 
Dam Fusion Constructs 
The TEAD3 cDNA was ordered from Transomic while the SMAD3 and CTCF cDNAs were generated 
from mRNA purified from HEK 293T cells. The cDNA was then amplified by PCR using primers 
containing homology arms to the lentiviral pLgw-EcoDam plasmid, kindly provided by the van 
Steensel lab. Using a Gibson cloning reaction (New England Biolabs), each DNA binding factor was 
inserted in frame with Dam on the N-terminus. 
Culture, Transduction, and Collection 
Each pLgw-EcoDam plasmid was transfected into HEK 293T cells along with the VSVG envelope 
protein (pCMV-VSVG) and the packaging vector, pSPAX2 (Figure 5A). Replication-deficient 
lentiviruses were collected via standard procedure [20].A human immortalized primary melanocyte 
cell line (hMELT) was a kind gift of the Sellers Lab [21] and was grown in Ham’s F12 supplemented 
with 7.5% FBS, 1% penicillin–streptomycin, 2 mmol/L L-glutamine, 50 ng/ml TPA, 100 µM IBMX, 1 
µM Na3VO4, and 50 µM dbcAMP. The cells were transduced to create stable cell lines expressing the 
fusion Dam-proteins (Figure 5B). 500 μg/mL of hygromycin was used to select for transduced cells 
over the course of 3 days. The lines were maintained with media containing 125 μg/mL of 
hygromycin. PCR amplification of genomic DNA was used to confirm integration of the lentiviruses. 
Cells were plated at two million cells per 10 cm plate and allowed to grow for approximately 24 hours 
before collection for DamID analysis.DNA was extracted from the hMELT cells that were lysed in lysis 
buffer (50mM Tris(pH 8.0), 0.1M EDTA (pH 8.0), 0.1M NaCl, and 1% SDS) and purified following a 
phenol:chloroform clean-up procedure [22]. The DNA was re-suspended in TE Buffer and the 
concentration analyzed via Qubit assay (Invitrogen). For each sample, 300 ng of DNA was incubated 
with or without DpnII. The digest was incubated at 37 °C for 16 hours. The 300ng of incubated DNA 
was then diluted to 5ng/μL for qPCR analysis (Figure 5C). 
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DamID Assay and Analysis 
5ng of DNA, 3 μL of 10 ng/μL primer, and 4 μL of SYBR mix (Bio-Rad) were loaded onto a 384 well 
plate in triplicate. Quantitative polymerase chain reaction (qPCR) was run on the on the genomic 
DNA of the fusion-containing cell lines with and without DpnII digestion (95oC, 10 min; 40x [95oC, 5 
sec; 65oC, 30 sec]; melt curve 65oC-95oC, 0.5oC/cycle, 5 sec/cycle). The presence of multiple peaks 
in the melt curve indicated non-specific binding and was used to remove primer sets. Negative control 
primer sets with higher Ct values in DpnII digested genomic DNA were excluded as well. Ct values 
that were determined to be outliers by the Dixon Q outlier test at 95% confidence within a triplicate 
were removed [23, 24]. An average Ct value was then determined for each triplicate. For DpnII 
treated samples, a ∆Ct value was calculated by ∆Ct = Ct DpnII treated – average Ct DpnII untreated. 
ΔCt values for all of the negative control regions were averaged. A ΔΔCt value was calculated for 
each sample by the difference of a ΔCt value and the negative control average ΔCt value. All data is 
reported as the triplicate average of 2-ΔΔCt. This returns the fold increase in methylation of a triplicate 
in comparison to the average among negative controls.  
Plots were generated to display relative confidence in Dam proximity at a given location. A normal 
distribution was generated for each primer set, n, with the function: 
𝑓𝑓𝑛𝑛(𝑥𝑥) = 𝐶𝐶(𝑛𝑛) ∗ 𝑒𝑒−(𝑥𝑥−𝜇𝜇 )22𝜎𝜎2  (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑛𝑛 1) where x is the chromosomal base pair value. Centering the 
GATC sequence sets (μ) to the base pair coordinate of the sequence. σ was chosen to be equal to 
1250/3. This value was selected because it would result in 99% of the distribution falling within 
1250bp of the Dam enzyme binding site. C(n) was a constant calculated by 
𝐶𝐶𝑤𝑤(𝑛𝑛) = (% 𝑃𝑃𝐸𝐸𝑃𝑃𝐸𝐸𝐸𝐸𝐸𝐸𝑃𝑃𝑒𝑒 )�𝐴𝐴𝑃𝑃𝑒𝑒𝐴𝐴𝐸𝐸𝐴𝐴𝑒𝑒  2−ΔΔCt  values  �(𝑁𝑁)𝑆𝑆𝐸𝐸𝐸𝐸𝑛𝑛𝑆𝑆𝐸𝐸𝐴𝐴𝑆𝑆𝑆𝑆𝑒𝑒𝑃𝑃𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑛𝑛𝐸𝐸𝑓𝑓  2−ΔΔCt  values (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑛𝑛 2), C(n) = Cw (n)Max �Cw (n)� ∗ 100 (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑛𝑛 3). In this 
way, C(n) was higher for strong and consistent Dam proximity results, reflecting a higher confidence. 
A value of f(x) equal to or above fifty was generally considered as evidence for an interaction site. 
The sum of the normal distributions for a given binding protein was used to visualize Dam methylation 
patterns.  
Primer Selection 
For the DamID assay, primer sets had to be designed for each region of interest (Table 1). Similar 
sets were designed as positive and negative controls for each of the DNA binding factors. Primer sets 
were developed to amplify regions of about 125bp containing at least one GATC sequence. With 
GATC sequences occurring on average every 200-300bp in the genome, any region of interest had 
several to choose from [15]. BLAST was used to remove primer sets that bind to secondary locations 
in the genome with high affinity [25].  
Results 
Three DNA-binding factors were selected for investigation: CTCF, SMAD3, and TEAD3. A previous 
study used ChIP and chromatin conformation capture to identify three CTCF binding sites in the 
INK/ARF locus [11]. These binding sites are located downstream of p16INK4a and in the promoter 
regions of p15INK4b and p14AR F(Figure 6)[11]. Further, it was shown that CTCF mediates differential 
INK/ARF chromatin looping structures in somatic, iPS, and senescent cells [11]. A known chromatin 
organizer involved in insulator activity and chromatin looping, CTCF binding to the INK/ARF locus and 
PRR could potentially reorganize the INK/ARF locus to alter gene accessibility [13, 14]. 
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The PRR was shown by luciferase assay to act as a regulatory element and had increased activity 
with when containing the CAD-associated risk allele [10]. Bioinformatic analysis also indicated that 
there is a putative SMAD3 binding motif in the PRR [10]. The risk allele disrupts this site suggesting 
the CAD SNP could alter SMAD3 binding and lead to INK/ARF deregulation. Further, SMAD3 is 
required for the anti-proliferative effects of TGF-β mediated by p16INK4a [10, 26]. 
It was previously shown that TEAD3 is a positive regulator of the INK/ARF locus. In particular, over-
expression of the transcription factor led to increased expression of p16INK4a [26]. However, 
homozygous cell lines for either of two CAD-associated SNPs did not respond to over expression of 
TEAD3 [26]. TEAD3 was shown by ChIP to bind these SNPs but the risk allele disrupted the binding 
[26]. Given that TEAD3 has been shown to be an important regulator of the INK/ARF locus and that 
TEAD3 fails to induce p16INK4a with the risk allele, it was chosen to be investigated [26]. Together, 
these data suggest that CTCF, SMAD3, and TEAD3 are candidates for mediating INK/ARF 
regulation. 
SNPs in the PRR are associated with the downregulation of transcripts emanating from the INK/ARF 
locus and other phenotypes including CAD and melanoma [7-9]. In order to investigate binding of 
CTCF, SMAD3, and TEAD3 to the INK/ARF locus, the DamID assay was utilized. The ECAD4 region 
had been described as having enhancer marks such as H3 monomethylation at lysine 4 
(H3K4me1)[7]. A TEAD3 binding site that is lost with the risk allele of a CAD-associated SNP also lies 
just downstream of this region [27]. For these reasons TEAD3 was chosen to be investigated with 
primer set ECAD4-1 (Figure 6). A GATC was found within the aforementioned putative SMAD3 
binding site. It shared proximity to a putative CTCF binding site in the PRR allowing investigation of 
several potential modes of regulation through one amplicon. Three primer sets dubbed PRR1, PRR2, 
and PRR3, were designed to examine this region (Figure 6). 
Positive control primer sets were designed for each DNA binding protein. Positive controls primer sets 
for Smad3, SMAD-PC-1 and SMAD-PC-2, lie within the Transgelin promoter where SMAD3 was 
previously shown to bind [28]. TEAD3 positive control primer sets, TEAD3-PC-1, TEAD3-PC-2, and 
TEAD3-PC-3, were selected within Connective Tissue Growth Factor (CTGF), a gene known to be 
regulated by TEAD3 [29]. I used the UCSC Genome Browser to visualize an ENCODE ChIP-Seq 
dataset for TEAD3 genomic binding and select specific regions to use as positive control amplicons 
[27, 30]. Of note, ENCODE data indicated that CTCF had a binding site near the TEAD3 positive 
controls [27]. In addition to this site, three known CTCF binding sites were investigated within the 
INK/ARF locus. It was previously shown that CTCF binds CDKN2B and the p14ARF transcriptional 
start site and that CTCF is brought into proximity of the p16INK4a transcriptional start site by chromatin 
looping [11, 12]. Therefore, four CTCF positive controls primer sets were made. The CTCF-PC-1 and 
CTCF-PC-2 primer sets fall within the CDKN2B. CTCF-PC-3 falls in the first exon of p14ARFand 
finally, CTCF-PC-4 lies in the p16INK4a promoter region (Figure 6). My selected TEAD3 and CTCF 
positive control amplicons indicated binding in my DamID assays (Figures 6, 8A, 9A). However, the 
SMAD3 positive control primer sets failed to amplify after multiple trials, suggesting that SMAD3 was 
not binding to these sites in hMELT cells. 
Negative controls for DamID were designed using an ENCODE ChIP-Seq dataset for each protein 
and visualized in the UCSC Genome Browser [27, 30]. Specifically, I searched for regions of the 
human genome containing no known binding sites for the proteins of interest. Ultimately, five negative 
control primer sets were selected to be used in my experiments: Chr04-NC-1, Chr06-NC-3, Chr06-
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NC-5, Chr06-NC-6, and Chr08-NC-1. These functioned well with no significant evidence of Dam 
interactions in any of the Dam fusion cell lines and a maximum C(n) value of 12.5 (Figure 8B). 
Once working controls were established, DamID analysis was done on each of the three cell lines. 
The Dam-SMAD3 cell line DNA was not strongly methylated at any of the tested regions within the 
INK/ARF locus or PRR (Figure 9). Interaction peaks that were seen did not exceed the confidence 
seen in negative controls (Figure 9). The exception was at the CTGF promoter region used as the 
TEAD3 positive control (Figure 8A). While this amplicon peak did rise above negative controls, it was 
still much smaller than the peaks of the other DNA binding factors in this region. As stated before, I 
was unable to detect SMAD3 binding at positive control regions (data not shown). 
Dam-TEAD3 showed strong evidence of DNA methylation at the positive control region in CTGF 
(Figure 8). Within the INK/ARF locus, there was no evidence of interaction with the p16INK4a 
transcriptional start site, while the p14ARF transcriptional start site showed a potential interaction 
(Figure 9A). However this signal was not significantly higher than background. There was more 
evidence for the interaction of TEAD3 with CDKN2B. Binding at ECAD4 was also confirmed. A weak 
TEAD3 binding peak within the PRR is close to that of the negative controls and likely represents 
background (Figure 9). 
The CTCF positive controls in the INK/ARF locus showed strong binding peaks indicating that the 
locus could be used effectively as a control (Figures 9A). Dam-CTCF showed low binding to ECAD4 
enhancer region. While there is a CTCF binding site in this region, it also lies about 2kb from the 
selected primer set and thus does not fall in the usual range of the Dam fusion [14, 15, 12]. In 
contrast, the PRR and CTGF primer sets all showed interactions with high confidence (Figures 8A, 
9B). CTGF has a known CTCF binding site and thus my results were expected. However, the site at 
the PRR was not previously shown and therefore, this data confirms a novel binding site for CTCF. 
Taken together, these data establish DamID as a useful tool for probing the occupancy of putative 
DNA binding sites within chromosome 9p21. 
Discussion 
DamID is an alternative to chromatin immunoprecipitation (ChIP) that can be used to investigate 
protein:DNA interactions [15, 16]. DamID provides several key advantages over ChIP. First, ChIP is 
reliant on having protein specific antibodies which are not available for all targets. Dam has a strong 
propensity to methylate GATC sequences [15, 16]. This is a disadvantage which can cause high 
background signals. However, methylation marks can persist on the DNA for an extended amount of 
time and are placed rapidly when Dam is brought into proximity of the DNA. This allows the assay, 
unlike ChIP, to be utilized in investigations of transient, loose, or indirect interactions [15, 32]. These 
same properties of the Dam enzyme allow for mapping of three-dimensional chromatin structure [18, 
19]. DamID also can be used for global analysis through next-generation sequencing [33]. 
DamID has some comparative weaknesses, nonetheless. A limitation that must be considered is the 
potential for the Dam enzyme to interfere with folding of proteins of interest [15]. Positive controls 
show continued function, but do not guarantee the efficiency of binding or function. As stated above, 
DamID does have strong background activity requiring effective negative controls and multiple 
experimental runs. The persistent nature of the methylation means that investigations of interactions 
under different conditions will continue to show marks from a previously treated state for some time. 
This can most easily be avoided by extending the time between treatments, allowing DNA replication 
to drown out the methylation. However, this cannot be applied to all systems such as quiescent and 
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senescent cells. DamID also does not differentiate between post-transcriptional modifications, where 
ChIP succeeds [15, 31, 34]. Methylation occurs quickly after Dam is brought into proximity of a GATC 
sequence but initial expression of the fusion is not immediate upon transduction [15].  
My technical triplicates tended to have values close to one another. Outliers were removed by the 
Dixon Q test with 96% confidence, but often deviated by near inconsequential amounts as low as 
0.01 Ct. Biological replicates did not, in general, retain this tight distribution. In particular, any two 
biological replicates could have vastly different values Ct values. While the magnitude of replicate 
values differed, signal at positive sites was consistently two-fold higher than the background. Signal 
at negative control locations or those that did not show evidence of binding remained consistent 
between replicates. Therefore, it is apparent that DamID can act as a binary test with only a few 
replicates. Primer sets near a binding site consistently exhibited signals two-fold or greater than the 
negative controls. However, quantitative binding was difficult to establish. Binding of a single 
transcription factor at one primer set showed increases ranging from two- to 966-fold over the 
controls. The large spread in the data led me to use an analysis method more reliant upon a binary 
threshold (Equation 2).It is possible that the variance between samples originates from the 
endogenous protein binding in competition with the fusion proteins. 
A large portion of the work done here was to establish these important components of the 
experiment. Nonetheless, once a cell line is established and controls are confirmed, DamID can be 
run at relatively high throughput. Measuring the binding of a particular Dam fusion to a new target can 
also be accomplished in a short amount of time.  
The negative controls were scattered throughout the genome but provided consistent evidence that 
DamID was working. Importantly, amplification at the negative control regions was consistently low as 
assessed by C(n) value (Equations 2, 3) and did not cross the two-fold threshold in most runs. This 
allowed for accurate identification of binding within unknown sites.  
Positive controls were established for use in Dam-CTCF and Dam-TEAD3 assays (Figures 8A, 9A). 
Strong peaks can be seen in each of the CTCF positive control sites (Figure 8A). CTCF binding is 
particularly clear in CDKN2B where the two primer sets were sufficiently close that their positive 
binding was additive. These controls worked consistently, showing a two-fold or higher increase over 
background. Future analyses of CTCF or TEAD3 DNA binding through DamID can use these primer 
sets as positive controls to compare to other regions. Despite the clear indication of binding through 
DamID, these positive controls did not exhibit Ct values as consistent as seen in the negative 
controls. The unfortunate effect of this is that the positive controls cannot be easily used to quantify 
levels of binding in unknowns or putative regions. The SMAD3 positive control primers were never 
found to work. Although there is a known SMAD3 interaction site in the Trangelin promoter there was 
no evidence of binding through DamID. Several proposed mechanisms would explain this result. One 
possibility is that the fusion of Dam to SMAD3 disrupts function of the transcription factor. 
Alternatively, the Dam-SMAD3 fusion may not be expressed. An immunoblot with an antibody against 
Dam or SMAD3 could confirm this explanation. Another possibility depends on the activity of SMAD3. 
Under normal conditions, SMAD3 is localized to both the cytoplasm and nucleus. Signaling initiated 
by transforming growth factor beta (TGF-β) stimulates nuclear import and the formation of a 
heteromeric complex with SMAD4. This complex then binds to DNA containing 5′-GTCT-3′ motifs 
[32]. Therefore, SMAD3 may not have a strong enough interaction with the positive control region in 
the absence of TGF-β. In the future, DamID could be run after TGF-β treatment to evaluate the 
validity of this explanation. 
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The DamID assay, preformed using Dam-CTCF, -TEAD3, and -SMAD3, returned several interesting 
results. Most notably, it was shown that a putative CTCF binding site in the PRR did indeed display 
binding. While this does not confirm chromatin looping between the PRR and the INK/ARF locus, it 
does support the possibility. Nonetheless, it demonstrates success of the DamID system in defining 
novel binding sites. The ECAD4 site also showed strong interaction with TEAD3, suggesting that the 
downstream putative binding site is utilized (Figure 9B). TEAD3 did show interaction with CDKN2B, 
which would support a mechanism by which it can regulate the INK4/ARF locus (Figure 9A). 
However, binding of TEAD3 was not observed near the transcriptional start sites of p16INK4a or 
p14ARF. Finally, a putative SMAD3 binding site in the PRR did not show evidence of binding. Due to 
the lack of a good positive control, it is possible my inability to detect SMAD3 binding was an artifact 
of a non-functional protein. Alternatively, induction of TGF-β signaling may be required before binding 
is evident. Though these are possibilities, a graduate student in the lab had previously used ChIP-
Seq to show that SMAD3 does not bind the PRR (data not shown). 
It was difficult to quantitatively compare the interaction of a transcription factor between PCR sites 
with high confidence due to the large variability between biological replicates. The chosen method 
depicts relative confidence in interaction and has several useful properties. First, it closely reflects the 
1250bp range of DamID because 99% of the peak is contained within that range. Further, it is 
weighted to have higher confidence in larger data sets with a stronger average amplification 
(Equation 2). In addition, a smaller standard deviation in the data would return higher confidence 
(Equation 2). The analysis is also additive such that the use of several proximal primer sets increases 
confidence that an interaction is real. In the meantime, data from primer sets far away from each are 
not additive and show no interaction. The additive nature of my analytical design also provides a 
potential method to narrow the likely window of transcription factor binding. Unfortunately, use of a 
normal distribution causes the ends of each binding peak to be comparatively small. This takes away 
from some of the advantages of using an additive analysis. In particular, this method is useful for 
increasing the confidence in binding sites with many proximal primer sets. On the other hand, primer 
sets that have a very small overlapping range are not as useful. Alternative analyses could potentially 
use primer sets with small overlaps to narrow the range of binding for any unknown interaction.  
Now that controls are established for CTCF and TEAD3, several new directions are feasible. Firstly, 
chromatin looping between the INK/ARF locus and PRR can be investigated. Transcription activator-
like effectors (TALEs) can bind DNA in a sequence specific manner and can be designed for a 
chosen sequence [35, 36]. TALEs have been effectively fused to several different classes of protein 
including nucleases and, importantly, epigenetic modifying domains [36]. A TALE-Dam fusion 
directed specifically to the PRR would help confirm chromatin looping. Only through chromatin 
looping would the TALE-Dam fusion be brought into proximity of, and methylate the INK/ARF locus 
(Figure 4). To confirm that CTCF is the mediator of this looping, CRISPR/Cas9 endonuclease or 
another designer nuclease could be used to remove the CTCF site in the PRR. If the INK/ARF 
methylation does not persist, CTCF would be determined as the primary mediator of the event.  
The establishment of controls and mapping of steady binding patterns now also allows for 
investigations of how DNA interactions change under different conditions. In particular, to study OIS, 
an inducible oncogene (e.g. NRASQ61R) could be inserted into the cell line [37]. By running DamID on 
both induced and not induced cells, differences in binding could potentially be observed. Alternatively, 
stable, constitutive expression of an oncogene could be achieved in one cell line which could be 
compared to a line not expressing the oncogene. Such a study could elucidate the mechanism for 
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OIS and eventually improve our understanding of how systems to protect against uninhibited cell 
growth are activated and why they fail. 
In sum, I have established DamID controls to profile CTCF and TEAD3 binding to the INK/ARF locus. 
Moving forward, PRR looping with the INK/ARF locus could be investigated and the mechanistic 
details of OIS illuminated. 
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Figure 1: A map of the INK4/ARF locus. Located on chromosome 9p21.3, the INK4/ARF locus 
contains encodes two tumor suppressor genes, CDKN2A and CDKN2B. Exons 2 and 3 of CDKN2A 
are shared by p14ARFand p16INK4a but each has a different starting exon. CDKN2B encodes p15INK4b. 
 
 
 
 
 
 
Figure 2: The INK/ARF locus controls progression through the cell cycle. A) p14ARF inhibits 
MDM2 interaction with p53, promoting cell cycle arrest and DNA repair. B) Retinoblastoma (Rb) 
regulates cell cycle progression from G1- to S-phase by binding to, and inhibiting the transcriptional 
activity of E2F. Phosphorylation of Rb alleviates this interaction, allowing for cell cycle progression. C) 
p15INK4b and p16INK4a inhibit the binding of cyclin D to CDK4/6, thereby preventing Rb phosphorylation 
and subsequent cell cycle progression. 
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Figure 3: An overview of the DamID assay.Pink bars above the DNA designate a methylated 
adenine. A) The E.Coli Dam protein will methylate GATC sequences near the binding sites of the 
fused DNA-binding factor. B) DpnII will not cut GATC sequences that are Dam-methylated. C) By 
performing PCR across a potential methylation site (Primers represented by green arrows), one can 
visualize the loss of digested sequences. 
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Figure 4: Investigating chromatin looping in using DamID. Linear DNA greater than 1250 bp from 
the binding site will not be methylated. However, DNA looping can bring additional sites in proximity 
to the Dam fusion protein. 
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Figure 5: An overview of the DamID procedure. Pink bars above the DNA designate a methylated 
adenine. A)  Lentiviral backbones are created that encode Dam-transcription factor fusions. Each 
backbone is transfected into 293t packaging cells with helper plasmids encoding viral structual 
proteins. Mature lentivirus is harvested from the media. B) Lentiviruses are placed on human primary 
melanocytes for infection. Hygromycin selection is performed to kill off any uninfected cells. C) DNA is 
isolated from melanocytes stably expressing the lentiviral constructs and digested with DpnII. SYBR-
based qPCR is performed around GATC sequences of interest to compare methylation status near 
potential binding sites of interest. 
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Figure 6: The relative location of known and putative DNA-binding sites as well as primer sets 
in the INK/ARF locus and regulatory region. Distances are not to scale. There is a distance of 
about 60kb between A and B. A) Primer sets in the INK/ARF locus with key features. B) Primer sets 
in the INK/ARF regulatory region.  
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Figure 7: Representative DamID results. Shown is agraph of therelative DNA abundance at each 
site as detected by qRT-PCR and normalized to the average value of each respective negative 
control. Representative results are shown for Dam-SMAD (A),Dam-CTCF (B), and Dam-TEAD3 (C). 
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Figure 8: Relative binding of CTCF, SMAD, and TEAD3 around CTGF (positive control) and 
negative controls. Peaks, centered at the assayed GATC sequence, are graphed as a normal 
distribution with standard deveations equal to 1/3 the range of Dam methylation.  The peak height 
represents relative confidence in binding as described in the methods. All images are similalry scaled. 
A) Binding in the proximity of the CTGF positive control. B) Binding detected within negative control 
primer sets. Although they are represented together here, the negative controls are not in proximity to 
each other in the genome. 
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Figure 9: Relative binding of CTCF, SMAD, and TEAD3 within the INK/ARF locusand regulatory 
region. Peaks, centered at the assayed GATC sequence, are graphed as a normal distribution with 
standard deveations equal to 1/3 the range of Dam methylation.  The peak height represents relative 
confidence in binding as described in the methods. All images are scaled in the same manner. A) 
Detected binding in the proximity of INK/ARF locus. B) Detected binding at the regulatory region 
approximately 90kb upstream of the INK/ARF locus. 
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Primer Sequence (5'->3') Location in hg38 
Chr04-NC-1 F TCACTTTCAGACACTGATGTTG Chr4:93587020-93587041 
Chr04-NC-1 R GAACAGAGGGAATAAAGAGAAATGATAG Chr4:93587128-93587101 
Chr06-NC-3 F GTCATTCCATGGGTACTAACCT Chr6:12984638-12984659 
Chr06-NC-3 R TATGAAACAAACTGCTCGGTTG Chr6:12984782-12984761 
Chr06-NC-5 F CTTGTGAGGACGGGTGTATG Chr6:12986740-12986759 
Chr06-NC-5 R ACTTCTCTAAACCTTTGCTTACCT Chr6:12986880-12986857 
Chr06-NC-6 F AAGGCAGCTTCTAGTTCCAAA Chr6:12987543-12987563 
Chr06-NC-6 R CTGAATGAGCTTTATTTGCTCAAGA Chr6:12987657-12987633 
Chr08-NC-1 F TGTCTCTCATTGTAAATTGTTGCAC Chr8:64039557-64039581 
Chr08-NC-1 R TAGAAAGTCAGATGCCATTACAGAA Chr8:64039751-64039727 
CTCF-PC-1 F GCAGGATTCGTACTTAAACATTGA Chr9:22008067-22008090 
CTCF-PC-1 R CATACTCAGTGCCCAGATTACA Chr9:22008206-22008185 
CTCF-PC-2 F CAATTCAGTCTATTCCTTGCATCTC Chr9:22008534-22008558 
CTCF-PC-2 R CGGAGGTGTGCATTCCAC Chr9:22008679-22008662 
CTCF-PC-3 F GACCTCTACCTCTAACTCACAAAG Chr9:21993503-21993526 
CTCF-PC-3 R CGACTTCCTGAAATGCTAACAAG Chr9:21993630-21993608 
CTCF-PC-4 F CGGACTCCATTCTCAAAGTCATA Chr9:21975740-21975762 
CTCF-PC-4 R GTGAAGGAGACAGGACAGTATTT Chr9:21975854-21975832 
TEAD3-PC-1 F GTCCTACACAAACAGGGACAT Chr6:13195144-131951464 
TEAD3-PC-1 R GGAGGAATGCTGAGTGTCAA Chr6:131951544-131951525 
TEAD3-PC-2 F CAGTCCGAGCGGTTTCTTT Chr6:131950682-131950700 
TEAD3-PC-2 R CAAGGGCCTATTCTGTCACTTC Chr6:131950828-131950807 
TEAD3-PC-3 F CCTCAAGATGCCTACCTGTAAA Chr6:131951917-131951938 
TEAD3-PC-3 R CGCGTCTTTGTTCTCTTTCTTG Chr6:131952018-131951997 
ECAD4-1 F TCTGCTTGCCTTCGTAACC Chr9:22096862-22096880 
ECAD4-1 R GCAAATCCAGCAGGCAAAG Chr9:22096973-22096955 
PRR-1 F CTGCCTATCTGACCATTGTACTT Chr9:22118951-22118973 
PRR-1 R TGATAGCATAGTGATTCATACTCCAG Chr9:22119049-22119024 
PRR-2 F AACTTGAGCTTGGGTTCAG Chr9:22119947-22119965 
PRR-2 R CCCATATTTCAGACATAACTTTCTC Chr9:22120062-22120038 
PRR-3 F TGTGAAGATTCAATGAGTTGTAACG Chr9:22120087-22120111 
PRR-3 R GCTGTCTGTAAGATACTGGGAAG Chr9:22120214-22120192 
Table 1: A list of primers used for DamID qPCR.  
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